Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865026 | 0.89 | FAAH (0.48) | RECQLKDM4EPKMUSP2SMN1; SMN2 | |
| SCHEMBL15864139 | 0.88 | FAAH (0.50) | RECQLKDM4EPKMFAAHGPR119 | |
| SCHEMBL25033884 | 0.81 | RECQL (0.46) | RECQLKDM4EPKMUSP2SMN1; SMN2 | |
| SCHEMBL26668749 | 0.81 | FPR2 (0.45) | FPR2RECQLKDM4EPKMUSP2 | |
| SCHEMBL2546063 | 0.81 | FPR2 (0.48) | FPR2RECQLKDM4EPKMFAAH | |
| SCHEMBL2979718 | 0.79 | BACE1 (0.47) | FPR2RECQLKDM4EPKMUSP2 | |
| SCHEMBL25832564 | 0.78 | FPR2 (0.48) | FPR2RECQLKDM4EPKMFAAH | |
| SCHEMBL189570 | 0.78 | FPR2 (0.51) | FPR2KDM4EPKMSMN1; SMN2GPR119 | |
| SCHEMBL2397802 | 0.77 | RECQL (0.50) | FPR2RECQLKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL29056036 | 0.77 | FPR2 (0.50) | FPR2KDM4EPKMGPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575586-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | Pfizer Japan Inc. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004054579-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | FPR2 1268/4885RECQL 4751/4885KDM4E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.